GlassScriptPhysician profile
Lauren Howe
NPI 1306216981
$28,007.84
in general payments reported to CMS, 2019-2025
30 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $252 · 2022: $1,816 · 2023: $3,147 · 2024: $8,351 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,816 · Consulting Fee: $2,518 · Travel and Lodging: $2,314 · Education: $839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,453.42 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,816.00 |
| Consulting Fee | $2,518.00 |
| Travel and Lodging | $2,313.53 |
| Education | $839.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $6,387.99 | 2022-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $3,350.93 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $3,183.16 | 2023-2025 | Nemluvio, Aklief, Oracea |
| Dermavant Sciences, INC. | $2,283.79 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $1,622.29 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,331.35 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Abbvie INC. | $1,117.92 | 2021-2025 | |
| Leo Pharma INC. | $1,100.76 | 2022-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $1,016.93 | 2021-2025 | Dupixent |
| Ucb, INC. | $954.14 | 2022-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $925.05 | 2023-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $890.93 | 2024-2025 | Zoryve |
| Genzyme Corporation | $790.00 | 2021-2025 | |
| Lilly USA, LLC | $643.13 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Organon LLC | $478.12 | 2025 | Vtama |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $281.52 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $268.98 | 2022-2025 | |
| Incyte Corporation | $238.43 | 2021-2025 | Opzelura |
| Epi Health, LLC | $223.08 | 2022 | |
| Medimetriks Pharmaceuticals, INC. | $173.05 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.77 | 2023-2024 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $141.55 | 2021-2025 | Jublia, Arazlo, Duobrii |
| Journey Medical Corporation | $134.70 | 2022-2023 | |
| Mayne Pharma Commercial LLC | $56.15 | 2025 | |
| Biofrontera INC. | $53.63 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Elekta, INC. | $51.26 | 2025 | Flexitron Hdr |
| Almirall LLC | $49.85 | 2023-2025 | Klisyri, Seysara |
| Takeda Pharmaceuticals U.S.A., INC. | $41.81 | 2025 | |
| Revance Therapeutics, INC. | $41.25 | 2024 | Daxi |
| Botanix Sb INC | $17.32 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Howe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.